About Opus Genetics
Opus Genetics is a company based in Durham (United States) founded in 2021 by Jason Menzo was acquired by Ocuphire in October 2024. Opus Genetics has raised $23.5 million across 3 funding rounds from investors including HHS, Ocuphire and Manning Family Foundation. The company has 18 employees. Opus Genetics offers products and services including Gene Therapy Pipeline and IRD Programs. Opus Genetics operates in a competitive market with competitors including Biological E, Vir Biotechnology, Vaxcyte, Cidara Therapeutics and EyePoint Pharmaceuticals, among others.
- Headquarter Durham, United States
- Employees 18
- Founders Jason Menzo
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website opusgtx.com
- Social LinkedIn X
- Acquired by Ocuphire (Oct 2024)
- Legal Name Opus Genetics, Inc.
- Annual Revenue$14.2 M (USD)29.15as on Dec 31, 2025
- Net Profit-$49.59 M (USD)13.8as on Dec 31, 2025
- EBITDA-$38.55 M (USD)-13.16as on Dec 31, 2025
- Total Equity Funding$23.5M (USD)
in 3 rounds
- Latest Funding Round$882.97K (USD), Grant
Sep 2024
- InvestorsHHS
& 4 more
- Employee Count18
- Acquired byOcuphire
(Oct 2024)
Products & Services of Opus Genetics
Opus Genetics offers a comprehensive portfolio of products and services, including Gene Therapy Pipeline and IRD Programs.
Develops treatments for inherited retinal diseases via gene targeting.
Focuses on mutations in genes causing vision loss in retinal disorders.
Funding Insights of Opus Genetics
Opus Genetics has successfully raised a total of $23.5M across 3 strategic funding rounds. The most recent funding activity was a Grant round of $882.97 thousand completed in September 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $23.5M
- Total Rounds 3
- Last Round Grant — $882,971
- First Round $19M
(Sep 2021)
- Investors Count 4
All 3 funding rounds of Opus Genetics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2024 | $882,971 | Grant | – | – | |
| Jun 2023 | $4.5M | Seed | – | – | – |
| Sep 2021 | $19M | Seed | – | RD Fund |
5 investors in total: 5 institutional.
Investors in Opus Genetics
Opus Genetics has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Ocuphire and Manning Family Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital is provided by Bios Partners for biotech innovation. | 2017 | biospartners.com | Fort Worth, United States | |
Investments are focused on retinal degeneration therapeutic solutions. | – | retinaldegenerationfund.org | Raleigh, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
Grants are awarded to advance health and community development. | 2003 | themanningfamilyfoundation.org | Charlottesville, United States | |
Therapeutics for refractive and retinal eye disorders are developed. | 2018 | ocuphire.com | West Bloomfield Township, United States |
Investor details for Opus Genetics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Opus Genetics
3 people are tracked at Opus Genetics (3 in leadership); the tracked headcount is 18.
| Name | Role | Group |
|---|---|---|
Jason Menzo | Co-Founder | Leadership |
Ben Yerxa | CEO | Leadership |
Sarah Callahan | Senior Director, Clinical Operations | Leadership |
Complete people profiles for Opus Genetics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Opus Genetics
Opus Genetics is a publicly listed company on the NASDAQ with ticker symbol IRD in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date24 Oct 2024
- Listed onNASDAQ: IRD
- Listed entityOpus Genetics, Inc.
- Exchange sectorHealth technology
- ISINUS67577R1023
- Share price$4.65 (+4.26% on the day) · 2026-10-09
- Market capitalisation$386.9M
- EPS (diluted, trailing year)$-1.38
- Volume (last session)1,257,290
Financials of Opus Genetics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $14.2M | -$49.6M | -$38.5M |
| 2024 | $11.0M | -$57.5M | -$34.1M |
| 2023 | $19.1M | -$10.0M | -$10.6M |
| 2022 | $39.9M | $17.9M | $18.2M |
| 2021 | $589,000 | -$56.7M | -$22.7M |
Detailed financial statements for Opus Genetics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Opus Genetics
5 dated milestones of Opus Genetics across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Opus Genetics is founded.
- Funding First funding round of $19.0M.
- Funding Latest funding round, Grant, of $883K.
- Exit Acquired by Ocuphire.
- IPO Lists on the stock exchange (IPO).
Competitors of Opus Genetics
Opus Genetics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biological E, Vir Biotechnology, Vaxcyte, Cidara Therapeutics and EyePoint Pharmaceuticals, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biologicale.com | 1953 | Hyderabad, India | – | 6,099 | Vaccines and therapeutics for multiple diseases are developed and marketed. | |
| vir.bio | 2017 | San Francisco, United States | $216M | 417 | Developer of therapeutics for the treatment of infectious diseases | |
| vaxcyte.com | 2013 | Foster, United States | $347M | 254 | Vaccines for infectious diseases are developed using cell-free protein synthesis. | |
| cidara.com | 2013 | San Diego, United States | $78.35M | 90 | Novel anti-infectives for bacterial and fungal infections are developed. | |
| eyepointpharma.com | 1987 | Watertown, United States | – | 49 | Small molecule therapeutics for ophthalmic disorders are developed. | |
| freeline.life | 2015 | Stevenage, United Kingdom | $273.69M | 152 | Gene therapy platform is developed for chronic disease treatments. | |
| valneva.com | 1999 | Lyon, France | $113.55M | – | Prophylactic vaccines for infectious diseases are developed and advanced. | |
| rezolutebio.com | 2012 | Denver, United States | – | 51 | Therapies for metabolic and orphan diseases are developed by Rezolute. | |
| seruminstitute.com | 1966 | Pune, India | – | 6,617 | Vaccines and immuno-biological drugs for infectious diseases are manufactured. |
Detailed competitors of Opus Genetics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Opus Genetics
The website of Opus Genetics (opusgtx.com) receives about 6.4K visits a month.
- Monthly visits6.4K
▼ 26% vs previous month
Websites whose visitors overlap most with Opus Genetics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| positron.com | 100% | 2.4K | – | View details |
Latest news on Opus Genetics
Complete news archive for Opus Genetics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Opus Genetics
10 companies that operate in the same segment as Opus Genetics (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Opus Genetics
Opus Genetics was founded in 2021.
Opus Genetics is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
Ben Yerxa is the current CEO of Opus Genetics.
Opus Genetics is a funded company, having raised a total of $23.5M across 3 funding rounds to date. The company's 1st funding round was a Seed of $19M, raised on Sep 2021.
Opus Genetics has 18 employees.
Annual revenue of Opus Genetics is $14.2M as on Dec 31, 2025.
Opus Genetics was founded in 2021 and is based in Durham, United States. Operations center on the biotechnology sector, where AAV-based gene therapies are developed to treat mutations causing Leber congenital amaurosis and related retinal dystrophies. The pipeline features OPGx-001, which targets LCA5 gene mutations, and OPGx-002, aimed at retinal dystrophy conditions. Leadership includes co-founder Jason Menzo and CEO Ben Yerxa.
Opus Genetics's top competitors include Vaxcyte, Serum Institute of India and EyePoint Pharmaceuticals.
Opus Genetics offers Gene Therapy Pipeline and IRD Programs.
Yes, Opus Genetics is publicly traded on NASDAQ under the ticker symbol IRD.
Opus Genetics has 5 investors. Key investors include HHS, Ocuphire, Manning Family Foundation, Bios Partners, and Retinal Degeneration Fund.
Opus Genetics operates through Opus Genetics, Inc.